Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
Level V
Where this comes from
- Record sourced from PubMed, PMID 27920180.
- Also identified by PMC identifier 5137244.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
Medical subject headings
- Chikungunya Fever
- Chikungunya virus
- Vaccines, Virus-Like Particle
- Viral Vaccines